Paravaccinia, unspecified
ICD-10 B08.04 is a billable code used to indicate a diagnosis of paravaccinia, unspecified.
Paravaccinia is a viral infection caused by the vaccinia virus, which is closely related to the variola virus that causes smallpox. It is primarily associated with individuals who have been vaccinated against smallpox, particularly in the context of occupational exposure, such as in veterinary settings or laboratories. The infection can manifest as a localized skin lesion that resembles vaccinia but does not have the same systemic implications as smallpox. Symptoms may include fever, malaise, and localized swelling or lesions at the site of infection. The condition is typically self-limiting, but in immunocompromised individuals, it can lead to more severe complications. Diagnosis is often made based on clinical presentation and history of vaccination. Treatment is generally supportive, focusing on symptom relief. Understanding paravaccinia is crucial for healthcare providers, especially in the context of vaccination programs and potential outbreaks, as it may present similarly to other viral infections.
Detailed patient history, vaccination status, and clinical findings.
Patients presenting with skin lesions post-vaccination.
Consideration of patient’s immune status and potential complications.
Photographic evidence of lesions, detailed descriptions of skin findings.
Evaluation of skin lesions that may be confused with other viral exanthems.
Differentiation from other dermatological conditions is crucial.
When a patient presents with paravaccinia after vaccination.
Record vaccination date and any adverse reactions.
Infectious disease specialists should document the vaccination history thoroughly.
Paravaccinia is a viral infection caused by the vaccinia virus, typically associated with individuals who have been vaccinated against smallpox. It presents with localized lesions and systemic symptoms.
Diagnosis is based on clinical presentation, vaccination history, and exclusion of other similar viral infections.
While generally self-limiting, paravaccinia can lead to more severe complications in immunocompromised individuals, necessitating careful monitoring.
